(Q45925043)

17 December 2017

title

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. (English)

1 reference

17 December 2017

1 reference

1 reference

1

1 reference

17 December 2017

Teresio Avitabile

4

object named as

Teresio Avitabile

1 reference

17 December 2017

author name string

Giovanni Li Volti

2

1 reference

17 December 2017

Michele Malaguarnera

3

1 reference

17 December 2017

Tijana Antic

5

1 reference

17 December 2017

Marco Vacante

6

1 reference

17 December 2017

Mariano Malaguarnera

7

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

17 December 2017

Expert Opinion on Pharmacotherapy

published in

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

page(s)

1875-1882

1 reference

17 December 2017

issue

12

1 reference

17 December 2017

Dietary fat and diabetes: a consensus view

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

The mysteries of lipoprotein(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Intensive statin therapy--a sea change in cardiovascular prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Carnitine metabolism and function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Lipoprotein(a): intrigues and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

L-carnitine improves glucose disposal in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Carnitine revisited: potential use as adjunctive treatment in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

Introductory Remarks: Risk Factor Levels and Variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903081745

10.1517/14656560903081745

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

19618992

1 reference

17 December 2017